ONE INJECTION EVERY 8 WEEKS SURPASSES ORAL HIV REGIMEN, STUDY FINDS
An injection once every eight weeks of the investigational drugs rilpivirine (made by Janssen) and cabotegravir (manufactured by ViiV) can keep HIV at undetectable levels in people switching over from oral antiretroviral medications, a new study shows.
Data released from the phase IIb study conducted by Janssen and ViiV showed that 95 percent of people who received the injection every 8 weeks continued to be virally suppressed at 32 weeks after switching from the oral regimen.
The study, called LATTE 2, included 309 adults who had achieved viral suppression in a prior study on an oral regimen of cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). In LATTE 2, they were then split into three groups: Those receiving a combination injection of cabotegravir and rilpivirine every eight weeks, a group receiving the injection every four weeks, or a group remaining on the oral regimen of cabotegravir and two NRTIs.
To read full article CLICK HERE